Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

High lead level in respiratory supplement

This article was originally published in The Tan Sheet

Executive Summary

FDA advises consumers not to use Vita Breath herbal supplements, manufactured by American Herbal Lab Inc. of Rosemead, Calif., because tests showed it contains lead at more than 10,000 times the maximum recommended level. New York City health officials notified FDA May 1 after a patient with lead poisoning reported taking Vita Breath and two other herbal products. The NYC officials analyzed a sample of Vita Breath and found it contained 1,100 parts per million of lead. FDA and New York and California officials are investigating Vita Breath, which American Herbal Lab says "supports healthy lung energy and respiratory system." The firm markets 46 products under the new vita brand. FDA's advisory comes after researchers asked the agency to tighten supplement regulation in part to block products with dangerous levels of lead from reaching the market (1"The Tan Sheet" Dec. 7, 2009)

You may also be interested in...



Herbal/Lead Study Calls For Pre-Market Approval, Draws Fire From Industry

A correlation between the use of some herbal supplements and increased blood lead levels in women should prompt tighter FDA regulation of supplements, including requiring pre-market approval, researchers say

Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar

Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.

UK MHRA Updates Assistive Tech And Borderline Regulations

Device classification themes were uppermost in April for the UK regulator, which issued key guidance in two areas prone to complexities. It also contributed to the MedTech Directorate’s one-year progress report.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS104090

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel